Previous close | 124.00 |
Open | 124.61 |
Bid | 124.40 x 0 |
Ask | 124.80 x 0 |
Day's range | 123.41 - 125.00 |
52-week range | 105.00 - 188.20 |
Volume | |
Avg. volume | 807,346 |
Market cap | 798.715M |
Beta (5Y monthly) | 0.25 |
PE ratio (TTM) | 124.00 |
EPS (TTM) | 0.01 |
Earnings date | 20 Jun 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 20 Jun 2019 |
1y target est | 234.67 |
Earnings preview of key companies reporting this week and what to look out for.
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support ongoing adva